Collagenase 3 Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24. pipeline Target constitutes close to 7 molecules. The latest report Collagenase 3 Pipeline Review, H1 2018, outlays comprehensive information on the Collagenase 3 Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24. targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type.
Collagenase 3 Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24. Collagenase3 MMP13 is a member of the matrix metalloproteinase MMP family of neutral endopeptidases. It plays a role in the degradation of extracellular matrix proteins including fibrillar collagen, fibronectin, TNC and ACAN, wound healing, tissue remodeling, cartilage degradation, bone development, bone mineralization and ossification.
The molecules developed by companies in Phase II, Preclinical and Discovery stages are 1, 5 and 1 respectively. Report covers products from therapy areas Musculoskeletal Disorders, Cardiovascular, Toxicology, Central Nervous System, Infectious Disease and Respiratory which include indications Osteoarthritis, Chemotherapy Induced Peripheral Neuropathy, Allergic Asthma, Alphavirus Infections, Arthralgia, Arthritis, Chikungunya Fever, Congestive Heart Failure Heart Failure, Edema, Myocardial Infarction, Osteoarthritis Pain and Seasonal Allergic Rhinitis.
Download FREE Sample of this Report @ https://www.24marketreports.com/report-sample/collagenase-3-matrix-metalloproteinase-13-or-mmp13-or-ec-3424pipeline-review-h1-2018-market-34
Furthermore, this report also reviews key players involved in Collagenase 3 Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24. targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape for Collagenase 3 Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.
The report reviews Collagenase 3 Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24. targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in Collagenase 3 Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24. targeted therapeutics and enlists all their major and minor projects
The report assesses Collagenase 3 Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24. targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Collagenase 3 Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24. targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Collagenase 3 Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Collagenase 3 Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24. development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Get the Complete Report & TOC @ https://www.24marketreports.com/life-sciences/collagenase-3-matrix-metalloproteinase-13-or-mmp13-or-ec-3424pipeline-review-h1-2018-market-34
Table of content
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Collagenase 3 Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24. Overview
Collagenase 3 Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24. Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Collagenase 3 Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24. Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Collagenase 3 Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24. Companies Involved in Therapeutics Development
Paradigm Biopharmaceuticals Ltd
Pfizer Inc
Takeda Pharmaceutical Co Ltd
Collagenase 3 Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24. Drug Profiles
pentosan polysulfate sodium Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF152 Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MMP13 for Osteoarthritis Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MMP13 for Osteoarthritis Pain and Inflammation Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MMP2,9 and 13 for Myocardial Infarction Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZF198 Drug Profile
Product Description
If You Have Any Question Related To This Report Contact Us @ https://www.24marketreports.com/enquire-now/collagenase-3-matrix-metalloproteinase-13-or-mmp13-or-ec-3424pipeline-review-h1-2018-market-34
CONTACT US:
276 5th Avenue, New York , NY 10001,United States
International: (+1) 646 781 7170
Fax: (+1) 212 634 4885
Email: [email protected]
Follow Us On linkedin :- https://www.linkedin.com/company/24-market-reports